<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="systematic-review"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098050</article-id><article-id pub-id-type="doi">10.3389/fmed.2025.1521587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xiaoling</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2775258/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Li</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Fan</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wei</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Congrong</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Yi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Tao</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Xing</surname><given-names>Shasha</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1881543/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Diao</surname><given-names>Haoyang</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3025759/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Mi</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Wenmei</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1873932/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Luo</surname><given-names>Erdan</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2041253/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Pharmacy, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Medical Affairs, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Obstetrics, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Traditional Chinese Medicine, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Good Clinical Practice, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Sarah M. Cohen, Hadassah Medical Center, Israel</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Fabian Bernhard Thadd&#x000e4;us Kraus, Ludwig Maximilian University of Munich, Germany</p><p>Marco Cavaco, Universidade de Lisboa, Portugal</p><p>Wen-Wei Lin, Kaohsiung Medical University, Taiwan</p></fn><corresp id="c001">*Correspondence: Erdan Luo, <email>luoerdan@sina.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1521587</elocation-id><history>
<date date-type="received"><day>02</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>18</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 Zhou, Xiao, Lai, Chen, Zhou, Deng, Wang, Xing, Diao, Tang, Guo and Luo.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhou, Xiao, Lai, Chen, Zhou, Deng, Wang, Xing, Diao, Tang, Guo and Luo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Antibodies have been widely used globally over the past decade and play an increasingly important role in modern medicine. Notably, significant advancements have been achieved in the realm of gynecology, particularly in gynecological cancers. This study endeavors to present a thorough overview of antibody-related drug clinical studies in gynecology registered on <uri xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</uri>, focusing on the basic characteristics of trials, geographical distribution, administration routes, indications, and targets. The analysis indicates a rising prevalence of antibody&#x02013;drug conjugates (ADCs), bispecific antibodies, and Fc-fusion proteins. This study will help develop new ideas for future research on antibodies in gynecology.</p></abstract><kwd-group><kwd>Clinicaltrials.gov</kwd><kwd>antibodies</kwd><kwd>gynecology</kwd><kwd>antibody&#x02013;drug conjugates</kwd><kwd>bispecific antibodies</kwd><kwd>Fc-fusion proteins</kwd><kwd>administration route</kwd></kwd-group><funding-group><award-group><funding-source id="cn1">Nanchong Social Science Planning Project North Sichuan Health Humanities Research Projects</funding-source><award-id award-type="contract" rid="cn1">NC25CB05</award-id></award-group><award-group><funding-source id="cn2"><institution-wrap><institution>Sichuan Provincial Department of Science and Technology</institution><institution-id institution-id-type="doi">10.13039/501100004829</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn2">2023YFG0277</award-id></award-group><award-group><funding-source id="cn3">Foundation of Chengdu Medical Scientific Research project</funding-source><award-id award-type="contract" rid="cn3">2023004</award-id></award-group><award-group><funding-source id="cn4">Yingcai Scheme, Chengdu Women's and Children's Central Hospital</funding-source><award-id award-type="contract" rid="cn4">YC2023010</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Nanchong Social Science Planning Project North Sichuan Health Humanities Research Projects (NC25CB05), Sichuan Provincial Department of Science and Technology (2023YFG0277), the Foundation of Chengdu Medical Scientific Research project (2023004), Yingcai Scheme, Chengdu Women's and Children's Central Hospital (YC2023010).</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="2"/><equation-count count="0"/><ref-count count="81"/><page-count count="13"/><word-count count="7864"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Obstetrics and Gynecology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>Antibody therapeutics have emerged as one of the most prominent sectors in the biopharmaceutical industry. Since the approval of the first monoclonal antibody in 1986, the field has experienced rapid and substantial expansion (<xref rid="ref1" ref-type="bibr">1</xref>). The development of antibodies has evolved from initial mouse-derived forms to chimeric, humanized, and fully human antibodies (<xref rid="ref2" ref-type="bibr">2</xref>). They have already made a significant impact on the overall sales of biopharmaceutical products in recent years (<xref rid="ref3" ref-type="bibr">3</xref>).</p><p>Antibody-related drugs exhibit high specificity for their target sites and demonstrate superior efficacy compared to conventional drugs, with fewer side effects (<xref rid="ref4" ref-type="bibr">4</xref>). These agents have been widely applied in gynecology, especially for the treatment of gynecological cancers (<xref rid="ref5" ref-type="bibr">5&#x02013;7</xref>). For instance, bevacizumab combined with paclitaxel and carboplatin has been considered first-line therapy for patients with primary peritoneal cancer, fallopian tube cancer, or epithelial ovarian cancer at stage III or IV (<xref rid="ref8" ref-type="bibr">8</xref>). Furthermore, the results of the KEYNOTE-826 study (<xref rid="ref9" ref-type="bibr">9</xref>) reveal that pembrolizumab in conjunction with chemotherapy, with or without bevacizumab, is recommended as a category 1 therapy for patients with metastatic, recurrent, or persistent cervical cancer (<xref rid="ref10" ref-type="bibr">10</xref>). Additionally, an increasing number of antibodies are currently under clinical trial evaluation (<xref rid="ref11" ref-type="bibr">11&#x02013;13</xref>). Despite these advancements, there is a lack of research providing a comprehensive overview of clinical trials involving antibody-related drugs in gynecology. To address this gap, registered clinical trials from <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> are reviewed in this study to provide new insights for future research into antibodies in gynecology.</p></sec><sec sec-type="materials|methods" id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec3"><label>2.1</label><title>Data sources</title><p>The keywords &#x0201c;antibody&#x0201d; and &#x0201c;marketed antibody-related drugs in gynecology&#x0201d; were used to thoroughly search data on <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>. This was identified from the databases of the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). Subsequently, entries containing &#x0201c;antibody&#x0201d; and specific terms&#x02014;&#x0201c;Denosumab,&#x0201d; &#x0201c;Bevacizumab,&#x0201d; &#x0201c;Pembrolizumab,&#x0201d; &#x0201c;Romosozumab,&#x0201d; &#x0201c;Dostarlimab,&#x0201d; &#x0201c;Tisotumab vedotin,&#x0201d; or &#x0201c;Mirvetuximab soravtansine&#x0201d;&#x02014;were retrieved in the field of &#x0201c;other terms.&#x0201d; The search was restricted to studies in &#x0201c;Early Phase 1, Phase 1, Phase 2, Phase 3, and Phase 4&#x0201d; with a study initiation date before 27 May 2024. Following the identification of all the keywords, the data were consolidated and duplicate entries were removed.</p><p>The protocols established in previous investigations of <ext-link xlink:href="https://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> were followed (<xref rid="ref14" ref-type="bibr">14&#x02013;16</xref>). A comprehensive manual review of all Medical Subject Headings (MeSH) and disease terms cataloged in the National Library of Medicine was conducted to identify those relevant to gynecology. Subsequently, the identified terms were used to extract potential gynecological clinical trials. The study conditions were manually reviewed by a team of trained researchers to select gynecology-related trials. The exclusion criteria were as follows: (1) studies in which antibodies were used as control drugs, and (2) clinical trials in which antibodies were utilized as adjunctive therapies, with a major focus on assessing other drugs rather than the antibodies themselves. Ultimately, a total of 589 clinical trials were included. The data retrieval process is illustrated in <xref rid="fig1" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Process of determining the included trials.</p></caption><graphic xlink:href="fmed-12-1521587-g001" position="float"/></fig><p>A variety of data were collected for analysis, including study title, condition, status, start date, trial phase, intervention, funder type, location, enrollment, administration route, and drug target. This study was not subjected to review by the institutional review board, since it used publicly available data without involving personal information.</p></sec><sec id="sec4"><label>2.2</label><title>Statistical analysis</title><p>Descriptive analysis was conducted using numerical and percentage formats for categorical variables, while data processing and analysis were performed via Microsoft Excel. Furthermore, network analysis was performed using Gephi to determine the locations and partnerships of the principal research institutions involved in the trials.</p></sec></sec><sec sec-type="results" id="sec5"><label>3</label><title>Results</title><sec id="sec6"><label>3.1</label><title>Basic characteristics</title><p>A total of 589 clinical trials involving antibody-related drugs in gynecology were analyzed, including 2 basket trials and 2 umbrella trials, which encompassed 646 antibody drugs. The fundamental characteristics of these trials are presented in <xref rid="tab1" ref-type="table">Table 1</xref>. The antibody-related drugs investigated comprised 17 (2.69%) murine, 12 (1.90%) chimeric, 458 (72.35%) humanized, and 146 (23.06%) human antibodies. It is important to note that Fc-fusion proteins were not included. Approximately half of the studies (291, 49.41%) had planned or actual enrollment of 50 participants or fewer. The majority of antibody drug trials were funded by sources categorized as &#x0201c;other,&#x0201d; comprising 308 studies (52.29%). Meanwhile, 236 studies (40.07%) received funding from industry sources, and 45 studies (7.64%) were funded by the National Institutes of Health (NIH). Furthermore, all antibody-related drugs were classified into five categories: canonical antibody, ADCs, Fc-fusion protein, and bispecific and radiolabeled antibody. <xref rid="fig2" ref-type="fig">Figure 2</xref> depicts the annual distribution of these different antibody-related drug formats, while <xref rid="fig3" ref-type="fig">Figure 3</xref> gives an overview of antibody clinical research.</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Basic characteristics of trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="2" rowspan="1">Types of antibodies</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Murine</td><td align="center" valign="top" rowspan="1" colspan="1">17(2.69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chimeric</td><td align="center" valign="top" rowspan="1" colspan="1">12(1.90)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Humanized</td><td align="center" valign="top" rowspan="1" colspan="1">458(72.35)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Human</td><td align="center" valign="top" rowspan="1" colspan="1">146(23.06)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">No. of site</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">239(40.58)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;2</td><td align="center" valign="top" rowspan="1" colspan="1">327(55.52)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="top" rowspan="1" colspan="1">23(3.90)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Enrollment of patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02264;50</td><td align="center" valign="top" rowspan="1" colspan="1">291(49.41)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">51&#x02013;100</td><td align="center" valign="top" rowspan="1" colspan="1">110(18.68)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">101&#x02013;500</td><td align="center" valign="top" rowspan="1" colspan="1">139(23.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">501&#x02013;1,000</td><td align="center" valign="top" rowspan="1" colspan="1">37(6.28)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1,001&#x02013;10,000</td><td align="center" valign="top" rowspan="1" colspan="1">12(2.04)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Funding source</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NIH</td><td align="center" valign="top" rowspan="1" colspan="1">45(7.64)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Industry</td><td align="center" valign="top" rowspan="1" colspan="1">236(40.07)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">308(52.29)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Recruitment status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" rowspan="1" colspan="1">213(36.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" rowspan="1" colspan="1">87(14.77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" valign="middle" rowspan="1" colspan="1">31(5.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" rowspan="1" colspan="1">132(22.41)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suspended</td><td align="center" valign="middle" rowspan="1" colspan="1">2(0.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Terminated</td><td align="center" valign="middle" rowspan="1" colspan="1">50(8.49)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown status</td><td align="center" valign="middle" rowspan="1" colspan="1">55(9.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Withdrawn</td><td align="center" valign="middle" rowspan="1" colspan="1">19(3.23)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Phase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Early Phase 1</td><td align="center" valign="middle" rowspan="1" colspan="1">6(1.02)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="middle" rowspan="1" colspan="1">85(14.43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="center" valign="middle" rowspan="1" colspan="1">50(8.49)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" rowspan="1" colspan="1">322(54.67)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="center" valign="middle" rowspan="1" colspan="1">9(1.53)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="center" valign="middle" rowspan="1" colspan="1">103(17.49)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td><td align="center" valign="middle" rowspan="1" colspan="1">14(2.38)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Interventional mode</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Parallel</td><td align="center" valign="middle" rowspan="1" colspan="1">243(41.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Single group</td><td align="center" valign="middle" rowspan="1" colspan="1">303(51.44)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sequential</td><td align="center" valign="top" rowspan="1" colspan="1">31(5.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Crossover</td><td align="center" valign="middle" rowspan="1" colspan="1">1(0.17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Factorial</td><td align="center" valign="middle" rowspan="1" colspan="1">1(0.17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" rowspan="1" colspan="1">10(1.70)</td><td rowspan="1" colspan="1">Characteristic</td><td rowspan="1" colspan="1">No. (%)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Allocation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Randomized</td><td align="center" valign="middle" rowspan="1" colspan="1">230(39.05)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-randomized</td><td align="center" valign="middle" rowspan="1" colspan="1">65(11.04)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" rowspan="1" colspan="1">294(49.92)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Masking</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Open</td><td align="center" valign="middle" rowspan="1" colspan="1">491(83.36)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Single</td><td align="center" valign="middle" rowspan="1" colspan="1">8(1.36)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Double</td><td align="center" valign="middle" rowspan="1" colspan="1">32(5.43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triple</td><td align="center" valign="middle" rowspan="1" colspan="1">17(2.89)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quadruple</td><td align="center" valign="middle" rowspan="1" colspan="1">37(6.28)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" rowspan="1" colspan="1">4(0.68)</td></tr></tbody></table><table-wrap-foot><p>Percentages may not sum to 100% due to rounding. Fc-fusion proteins are not included in different types of antibodies.</p></table-wrap-foot></table-wrap><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Annual number of different formats of antibody-related drugs in gynecology until May 27, 2024.</p></caption><graphic xlink:href="fmed-12-1521587-g002" position="float"/></fig><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Overview of antibody trials. <bold>(A)</bold> The number of trials in each phase per year from 1996 to 2024; <bold>(B)</bold> the number of trials in each phase in various antibody types.</p></caption><graphic xlink:href="fmed-12-1521587-g003" position="float"/></fig></sec><sec id="sec7"><label>3.2</label><title>Geographical distribution</title><p>There were 566 trials conducted by 32 countries after the exclusion of trials lacking geographical information. In terms of regional distribution, North America enrolled the largest number of antibody trials (341, 57.89%), followed by East Asia (122, 20.71%) and Europe (80, 13.58%), while other regions had limited trials on this issue. As for countries, the United States possessed an obvious advantage in the development of antibody-related drugs, conducting 335 trials, which accounted for more than half of the world. China represented the most in Asia, with 104 trials. <xref rid="fig4" ref-type="fig">Figure 4</xref> shows the distribution of clinical trials.</p><fig position="float" id="fig4"><label>Figure 4</label><caption><p>Distribution of clinical trials until May 27, 2024.</p></caption><graphic xlink:href="fmed-12-1521587-g004" position="float"/></fig><p>In addition to the aforementioned leading countries, there were 124 trials conducted across multiple countries, which illustrated a network of international cooperation among trial sites. A total of 63 countries participated in these international multi-center trials, of which the United States served as the leading site in 97 instances and collaborated with up to 24 different countries. The primary collaborators with the United States included Australia (17 trials), Canada (16 trials), and Belgium (15 trials). <xref rid="fig5" ref-type="fig">Figure 5</xref> illustrates the interconnection between the participating countries.</p><fig position="float" id="fig5"><label>Figure 5</label><caption><p>International cooperation network of trials. Each node represented a country, and the edge showed the cooperate connection between countries. The size of node represented the frequency of cooperation. Regions were represented by different colors.</p></caption><graphic xlink:href="fmed-12-1521587-g005" position="float"/></fig></sec><sec id="sec8"><label>3.3</label><title>Administration routes</title><p>Intravenous (IV) injection constituted the predominant method of antibody-related drug administration, which represented 568 cases (87.93%). Additionally, Subcutaneous (SC) injection was utilized in 72 cases (11.15%), intraperitoneal injection in 3 cases (0.46%), and vaginal administration in 1 case (0.15%). It is worth noting that two clinical trials used dual administration routes: combined IV and SC administration, and combined IV and intraperitoneal administration. <xref rid="fig6" ref-type="fig">Figure 6</xref> illustrates the annual number of registered clinical trials categorized by drug administration.</p><fig position="float" id="fig6"><label>Figure 6</label><caption><p>Annual number of antibody drug clinical trials in gynecology by drug administration until May 27, 2024.</p></caption><graphic xlink:href="fmed-12-1521587-g006" position="float"/></fig></sec><sec id="sec9"><label>3.4</label><title>Indications</title><p>Antibodies utilized for treating gynecological cancers were predominantly represented in clinical studies. These included ovarian cancer (158, 26.83%), cervical cancer (107, 18.17%), endometrial cancer (66, 11.21%), gestational trophoblastic neoplasm (7, 1.19%), uterine cancer (4, 0.68%), vulvar tumor (4, 0.68%), Paget&#x02019;s disease of the vulva (1, 0.17%), and multiple cancers (173, 29.37%). Furthermore, antibodies were used in 63 studies (10.70%) that addressed osteoporosis in postmenopausal women. It is noteworthy that a relatively small number of registered clinical trials have explored antibodies for conditions such as endometriosis (3, 0.51%), genital herpes (1, 0.17%), ovarian insufficiency (1, 0.17%), and contraception (1, 0.17%). <xref rid="fig7" ref-type="fig">Figure 7</xref> illustrates the distribution of clinical trials according to indications.</p><fig position="float" id="fig7"><label>Figure 7</label><caption><p>Number of new antibody drug clinical trials in gynecology by indications until May 27, 2024.</p></caption><graphic xlink:href="fmed-12-1521587-g007" position="float"/></fig></sec><sec id="sec10"><label>3.5</label><title>Targets</title><p>All the developing antibody-related drugs that are currently undergoing clinical trials in gynecology were cataloged systematically. The developed antibody-related drugs in gynecological clinical trials are summarized in <xref rid="tab2" ref-type="table">Table 2</xref>. Currently, there are 44 antibodies in gynecological clinical development, but approximately 34% act on just 5 validated and novel targets. Predominantly, mesothelin emerged as the most prevalent (4, 9.09%), followed by programmed cell death protein 1 (PD-1) (3, 6.82%), folate receptor <italic>&#x003b1;</italic> (FR&#x003b1;) (3, 6.82%), receptor tyrosine-protein kinase erbB-2 (HER2) (3, 6.82%), and T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domain (TIGIT) (2, 4.55%).</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Target and indication of developing antibody-related drugs in gynecological clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Antibody type/name</th><th align="left" valign="top" rowspan="1" colspan="1">Target</th><th align="left" valign="top" rowspan="1" colspan="1">Phase</th><th align="left" valign="top" rowspan="1" colspan="1">Trial number</th><th align="left" valign="top" rowspan="1" colspan="1">Study Status</th><th align="left" valign="top" rowspan="1" colspan="1">Indication</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="6" rowspan="1">Canonical</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Balstilimab</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03495882</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03104699</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03894215</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06095674</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oregovomab</td><td align="left" valign="top" rowspan="1" colspan="1">CA125</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04498117</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04938583</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01616303</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05335993</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BAT1308</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06321068</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06123884</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZB-06</td><td align="left" valign="top" rowspan="1" colspan="1">CD52g</td><td align="left" valign="top" rowspan="1" colspan="1">early phase1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04731818</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Contraception</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zalifrelimab</td><td align="left" valign="top" rowspan="1" colspan="1">CTLA4</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03495882</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Utomilumab</td><td align="left" valign="top" rowspan="1" colspan="1">4-1BB</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03318900</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tiragolumab</td><td align="left" valign="top" rowspan="1" colspan="1">TIGIT</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04300647</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical Cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sirexatamab</td><td align="left" valign="top" rowspan="1" colspan="1">DKK1</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03395080</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Setrusumab</td><td align="left" valign="top" rowspan="1" colspan="1">SOST</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01406548</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Osteoporosis in postmenopausal women</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rulonilimab</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06226350</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ociperlimab</td><td align="left" valign="top" rowspan="1" colspan="1">TIGIT</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04693234</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Murlentamab</td><td align="left" valign="top" rowspan="1" colspan="1">AMHRII</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02978755</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MK-4830</td><td align="left" valign="top" rowspan="1" colspan="1">ILT4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05446870</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Matuzumab</td><td align="left" valign="top" rowspan="1" colspan="1">EGFR</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT00073541</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mapatumumab</td><td align="left" valign="top" rowspan="1" colspan="1">TRAIL-R1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01088347</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Magrolimab</td><td align="left" valign="top" rowspan="1" colspan="1">CD47</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03558139</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HMI-115</td><td align="left" valign="top" rowspan="1" colspan="1">PRLR</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05101317</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Endometriosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDIT101</td><td align="left" valign="top" rowspan="1" colspan="1">Glycoprotein B</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04165122</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Herpes genitalis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ganitumab</td><td align="left" valign="top" rowspan="1" colspan="1">IGF-1R</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT00719212</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EMD 273066</td><td align="left" valign="middle" rowspan="1" colspan="1">EPCAM</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT00132522</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDX-1140</td><td align="left" valign="top" rowspan="1" colspan="1">CD40</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05231122</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carotuximab</td><td align="left" valign="middle" rowspan="1" colspan="1">endoglin</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01381861</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amatuximab</td><td align="left" valign="top" rowspan="1" colspan="1">Mesothelin</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT00325494</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NP137</td><td align="left" valign="top" rowspan="1" colspan="1">netrin-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04652076</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">STRO-002</td><td align="left" valign="top" rowspan="1" colspan="1">FR&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03748186</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05870748</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05200364</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anetumab Ravtansine</td><td align="left" valign="top" rowspan="1" colspan="1">Mesothelin</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03587311</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02751918</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HS-20089</td><td align="left" valign="top" rowspan="1" colspan="1">B7-H4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06014190</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IMGN151</td><td align="left" valign="top" rowspan="1" colspan="1">FR&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05527184</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Trastuzumab duocarmazine</td><td align="left" valign="top" rowspan="1" colspan="1">HER2</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04205630</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DP303c</td><td align="left" valign="top" rowspan="1" colspan="1">HER2</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04828616</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RC88</td><td align="left" valign="top" rowspan="1" colspan="1">Mesothelin</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06173037</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Farletuzumab ecteribulin</td><td align="left" valign="top" rowspan="1" colspan="1">FR&#x003b1;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05613088</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Raludotatug deruxtecan</td><td align="left" valign="top" rowspan="1" colspan="1">CDH6</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04707248</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DMOT4039A</td><td align="left" valign="top" rowspan="1" colspan="1">Mesothelin</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01469793</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DMUC4064A</td><td align="left" valign="top" rowspan="1" colspan="1">MUC16</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02146313</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BNT323/DB-1303</td><td align="left" valign="top" rowspan="1" colspan="1">HER2</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06340568</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fc-fusion protein</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Batiraxcept</td><td align="left" valign="top" rowspan="1" colspan="1">GAS6</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05826015</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04019288</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03639246</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SL-172154</td><td align="left" valign="top" rowspan="1" colspan="1">SIRP&#x003b1;/CD47</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05483933</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04406623</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SHR-1701</td><td align="left" valign="top" rowspan="1" colspan="1">PD-L1/TGF-&#x003b2;</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05179239</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" colspan="6" rowspan="1">Bispecific</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Navicixizumab</td><td align="left" valign="top" rowspan="1" colspan="1">VEGF/DLL4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05043402</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03030287</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZG005</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1/TIGIT</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06241235</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ubamatamab</td><td align="left" valign="top" rowspan="1" colspan="1">CD3/MUC16</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03564340</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REGN5668</td><td align="left" valign="top" rowspan="1" colspan="1">MUC16xCD28</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04590326</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vudalimab</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1/CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05032040</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Multiple gynecological cancers</td></tr><tr><td align="left" valign="top" colspan="6" rowspan="1">Canonical</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Balstilimab</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03495882</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03104699</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03894215</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06095674</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oregovomab</td><td align="left" valign="top" rowspan="1" colspan="1">CA125</td><td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04498117</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04938583</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01616303</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT05335993</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BAT1308</td><td align="left" valign="top" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06321068</td><td align="left" valign="top" rowspan="1" colspan="1">Recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Endometrial cancer</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Phases 2&#x02013;3</td><td align="left" valign="top" rowspan="1" colspan="1">NCT06123884</td><td align="left" valign="top" rowspan="1" colspan="1">Not recruiting</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZB-06</td><td align="left" valign="top" rowspan="1" colspan="1">CD52g</td><td align="left" valign="top" rowspan="1" colspan="1">early phase1</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04731818</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Contraception</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zalifrelimab</td><td align="left" valign="top" rowspan="1" colspan="1">CTLA4</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03495882</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Cervical cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Utomilumab</td><td align="left" valign="top" rowspan="1" colspan="1">4-1BB</td><td align="left" valign="top" rowspan="1" colspan="1">Phases 1&#x02013;2</td><td align="left" valign="top" rowspan="1" colspan="1">NCT03318900</td><td align="left" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">Ovarian cancer</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec11"><label>4</label><title>Discussion</title><p>Since 1996, research into antibodies has significantly expanded in the field of gynecology. Innovative clinical trials, such as umbrella and basket trials, have been implemented to advance the development of antibody-related drugs in the field of gynecology. This study identified two basket trials (NCT04965519 and NCT03827837) and two umbrella trials (NCT03699449 and NCT03574779). Basket trials are characterized by the evaluation of targeted therapy for multiple diseases that share common molecular alterations. Umbrella trials involve the assessment of multiple targeted therapies within a single disease and can be further classified into various subgroups (<xref rid="ref17" ref-type="bibr">17</xref>). The advantage of basket trials lies in the ability to test smaller sample sizes for a given tumor type, which facilitates research in less common tumor types. By contrast, umbrella trials allow for a more comprehensive analysis of treatment for a specific tumor type (<xref rid="ref18" ref-type="bibr">18</xref>). The application of these novel clinical trials in gynecology is anticipated to accelerate the evaluation and approval of antibody-related drugs and promote molecular-based individualized treatment strategies (<xref rid="ref19" ref-type="bibr">19</xref>, <xref rid="ref20" ref-type="bibr">20</xref>). In addition, innovative forms, such as ADCs, bispecific antibodies, and Fc-fusion proteins, have gained prominence and are the subjects of extensive investigation. In this review, studies were divided into four distinct groups according to the development of antibody-related drugs.</p><sec id="sec12"><label>4.1</label><title>Canonical antibodies</title><p>Canonical antibodies exhibit a complete antibody structure, which contains two light chains and two full-length heavy chains (<xref rid="ref21" ref-type="bibr">21</xref>). According to research, these antibodies represent more than 80% of all clinical trials in the field of gynecology.</p><p>Since the approval of ipilimumab in 2011, immune checkpoint inhibitors have significantly advanced the treatment of gynecological malignancies (<xref rid="ref22" ref-type="bibr">22</xref>). In this field, significant inhibitors encompass PD-L1, PD-1, CTLA-4, and LAG-3 (<xref rid="ref23" ref-type="bibr">23</xref>), among which PD-1/PD-L1 is the most extensively studied (<xref rid="ref24" ref-type="bibr">24</xref>). Pembrolizumab and dostarlimab have been approved by the FDA to treat gynecological cancers (<xref rid="ref21" ref-type="bibr">21</xref>). An increasing number of real-world studies contribute to the expanding body of evidence that supports the use of PD-1 inhibitors for recurrent or advanced gynecologic cancers. In a multi-center retrospective cohort study, Korean patients with recurrent endometrial cancer were administered pembrolizumab in combination with lenvatinib for a median duration of 4.5&#x0202f;cycles. During this period, the disease control rate was 76.2% (95% CI, 61.9&#x02013;88.1), and the best objective response rate was 23.8% (95% CI, 11.9&#x02013;38.1) (<xref rid="ref25" ref-type="bibr">25</xref>). The most common treatment-related adverse events included fatigue, hypertension, and hypothyroidism. Additionally, another retrospective study suggested that a lower dosage of pembrolizumab represents a cost-effective and efficacious treatment strategy for patients with refractory gynecologic cancer (<xref rid="ref26" ref-type="bibr">26</xref>).</p><p>The vascular endothelial growth factor (VEGF) serves as a crucial mediator in the process of neovascularization, which is predominantly secreted by cancer cells (<xref rid="ref27" ref-type="bibr">27</xref>). Bevacizumab is the first anti-angiogenic agent approved for oncological use. Numerous clinical trials have demonstrated the efficacy of bevacizumab in the treatment of gynecologic malignancies (<xref rid="ref28" ref-type="bibr">28</xref>). There is an increasing body of evidence that supports its efficacy and safety in routine clinical practice. In a retrospective study, bevacizumab was found to be effective and well-tolerated in the real-world treatment of ovarian cancer (<xref rid="ref29" ref-type="bibr">29</xref>). Furthermore, a multi-institutional retrospective cohort study indicated that bevacizumab maintenance therapy prolonged progression-free survival for metastatic, recurrent, or persistent cervical cancer (<xref rid="ref30" ref-type="bibr">30</xref>).</p><p>In addition, canonical antibodies are also used in the treatment of postmenopausal osteoporosis (<xref rid="ref31" ref-type="bibr">31</xref>). Notably, denosumab, a fully human antibody targeting RANK-L (<xref rid="ref32" ref-type="bibr">32</xref>), and romosozumab, a humanized monoclonal antibody targeting sclerostin (SOST) (<xref rid="ref33" ref-type="bibr">33</xref>), are utilized in this therapeutic context.</p></sec><sec id="sec13"><label>4.2</label><title>ADCs</title><p>ADCs have emerged as one of the most promising therapeutic modalities in oncology due to their ability to provide tumor cells with chemotherapy in a more targeted and safer manner (<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref35" ref-type="bibr">35</xref>). ADCs comprise a highly selective antibody, a cytotoxic payload, and a linker connecting the two components (<xref rid="ref36" ref-type="bibr">36</xref>). Currently, several ADCs have acquired FDA approval for the treatment of gynecologic cancers, including mirvetuximab soravtansine for ovarian cancer and tisotumab vedotin for cervical cancer (<xref rid="ref37" ref-type="bibr">37</xref>). Although no ADCs have been approved for endometrial cancer, 8 clinical trials (NCT04205630, NCT06132958, NCT03836157, NCT04251416, NCT06340568, NCT03835819, NCT03832361, and NCT04585958) have been identified to address this unmet critical need. Notably, mirvetuximab soravtansine is currently being evaluated in two phase II clinical trials for endometrial cancer (NCT03835819 and NCT03832361).</p><p>Fam-trastuzumab deruxtecan-nxki (T-DXd) contains a topoisomerase I inhibitor payload, a cleavable tetrapeptide linker, and the anti-HER2 antibody trastuzumab (<xref rid="ref38" ref-type="bibr">38</xref>). On 5 April 2024, the approval of T-DXd was accelerated by the FDA to treat adults with unresectable or metastatic HER2-positive (IHC3+) solid tumors. Previous clinical trials have suggested its potential efficacy in patients with endometrial cancer (<xref rid="ref39" ref-type="bibr">39</xref>). In the STATICE trial, patients with endometrial cancer expressing HER2 were categorized into HER2-low and HER2-high expression groups. The overall response rate was 70.0% (95% CI, 34.8&#x02013;93.3) for the HER2-low group and 54.5% (95% CI, 32.2&#x02013;75.6) for the HER2-high group. These results indicated that T-DXd is effective in patients with endometrial cancer, irrespective of the HER2 expression status (<xref rid="ref40" ref-type="bibr">40</xref>). Furthermore, the combination of T-DXd and olaparib was assessed in HER2-expressing cancers, including an extension to patients with endometrial cancer (NCT04585958).</p><p>Sacituzumab govitecan, ADCs against trophoblast cell surface antigen-2 (Trop-2), has demonstrated its potential efficacy in the treatment of endometrial cancer (<xref rid="ref41" ref-type="bibr">41</xref>). In a Phase I/II basket study, the objective response rate was 22.2% (95% CI, 6.4&#x02013;47.6) in the endometrial cancer cohort (<xref rid="ref42" ref-type="bibr">42</xref>). Currently, a Phase II study of sacituzumab govitecan in patients with persistent or recurrent endometrial carcinoma is ongoing (NCT04251416).</p><p>However, in this context, clinical data on other ADCs remain limited.</p></sec><sec id="sec14"><label>4.3</label><title>Bispecific antibodies</title><p>Bispecific antibodies are designed to simultaneously bind to separate antigenic epitopes or distinct antigens (<xref rid="ref43" ref-type="bibr">43</xref>). Compared with traditional antibodies, bispecific antibodies exhibit greater specificity, which contributes to improved therapeutic efficacy and safety, while reducing the likelihood of adverse reactions (<xref rid="ref44" ref-type="bibr">44</xref>). This characteristic makes bispecific antibodies a promising strategy in cancer therapy (<xref rid="ref45" ref-type="bibr">45</xref>). An increasing number of bispecific antibodies with diverse mechanisms are currently under development for oncological applications, including checkpoint inhibitors (CPIs), T-cell engagers (TCEs), natural killer cell engagers (NKCEs), and immune cell engagers (ICEs) (<xref rid="ref46" ref-type="bibr">46</xref>). In the realm of gynecological cancer, the majority of bispecific antibodies in registered clinical trials are concentrated on checkpoint inhibition. Notably, catumaxomab (NCT00189345, NCT00563836), navicixizumab (NCT05043402, NCT03030287), REGN5668 (NCT04590326), and ubamatamab (NCT03564340) are identified as agents targeting CD3xEpCAM, VEGFxDLL4, MUC16xCD28, and CD3xMUC16, respectively. A selection of representative findings is described in this subsection.</p><p>Cadonilimab is a bispecific antibody against PD-1 and CTLA4, which has completed two Phase II studies in patients with metastatic or recurrent cervical cancer (NCT04380805, NCT04868708). The findings of these studies indicated that cadonilimab may provide patients with substantial therapeutic benefits (<xref rid="ref47" ref-type="bibr">47</xref>, <xref rid="ref48" ref-type="bibr">48</xref>). In China, cadonilimab was approved in June 2022 for the treatment of metastatic cervical cancer based on these promising outcomes (<xref rid="ref49" ref-type="bibr">49</xref>). Furthermore, several clinical studies involving cadonilimab are currently ongoing (NCT05687851, NCT05824494, NCT06066216, NCT04982237, NCT05227651, and NCT05932212).</p><p>Navicixizumab is a bispecific agent that targets both DLL4 and VEGF (<xref rid="ref50" ref-type="bibr">50</xref>). A Phase 1a study of navicixizumab provided preliminary evidence of anti-tumor activity in ovarian cancer, with manageable toxicity (<xref rid="ref51" ref-type="bibr">51</xref>). A subsequent Phase 1b study combining navicixizumab with paclitaxel (NCT03030287) demonstrated an ORR of 43.2% (95% CI, 28.3&#x02013;59.0) in patients with platinum-resistant ovarian cancer. Furthermore, 90.9% of patients experienced treatment-related adverse events, including hypertension, fatigue, and headaches (<xref rid="ref52" ref-type="bibr">52</xref>). A Phase III trial to assess the efficacy and safety of navicixizumab in the treatment of ovarian cancer is currently underway (NCT05043402).</p></sec><sec id="sec15"><label>4.4</label><title>Fc fusion proteins</title><p>Fc fusion proteins contain the Fc domain of an immunoglobulin (IgG) and a desired linked protein (<xref rid="ref53" ref-type="bibr">53</xref>). Compared to traditional antibodies, Fc fusion proteins exhibit an extended half-life, multiple targeting capabilities, and superior specificity (<xref rid="ref54" ref-type="bibr">54</xref>). Currently, there are 13 studies on Fc fusion proteins in the field of gynecology. This report highlights the bifunctional fusion proteins Bintrafusp alfa (NCT04246489, NCT04551950), SHR-1701 (NCT05179239), and SL-172154 (NCT05483933, NCT04406623).</p><p>Bintrafusp alfa is a bifunctional fusion protein that comprises an extracellular domain of TGF-<italic>&#x003b2;</italic>receptor II fused to a human IgG1 monoclonal antibody against PD-L1 (<xref rid="ref55" ref-type="bibr">55</xref>). This agent has completed both Phase 1 and Phase 2 clinical trials in patients with metastatic or recurrent cervical cancer (NCT04551950, NCT04246489). The findings of these studies have confirmed the safety profile and clinical efficacy of Bintrafusp alfa. Anemia is the most common treatment-related adverse event (<xref rid="ref56" ref-type="bibr">56</xref>, <xref rid="ref57" ref-type="bibr">57</xref>).</p><p>SHR-1701 is a bifunctional fusion protein that comprises an extracellular domain of TGF-&#x003b2; II and an antibody targeting PD-L1 (<xref rid="ref58" ref-type="bibr">58</xref>). Recent data have indicated that SHR-1701 has an ORR of 15.6% in patients with metastatic or recurrent cervical cancer. Additionally, 11 patients (34.4%) experienced treatment-related adverse events of grade 3 or grade 4 severity. Consequently, SHR-1701 may be a potential therapeutic option for patients with cervical cancer (<xref rid="ref59" ref-type="bibr">59</xref>). Currently, the safety and efficacy of SHR-1701 are being evaluated in a Phase 3 clinical trial (NCT05179239).</p><p>SL-172154 is a hexameric fusion protein that comprises SIRP&#x003b1; and CD40L domains connected by an inert Fc linker. This agent has completed a Phase 1 clinical trial in ovarian cancer patients (NCT04406623). Additionally, a subsequent Phase 1 trial is currently underway, which targets patients with platinum-resistant ovarian cancer (NCT05483933).</p></sec><sec id="sec16"><label>4.5</label><title>Challenges</title><sec id="sec17"><label>4.5.1</label><title>Subcutaneous delivery of antibodies</title><p>Historically, antibody-related drugs are delivered by IV injection due to their inherent physicochemical and biological characteristics (<xref rid="ref60" ref-type="bibr">60</xref>). However, this method has several disadvantages, including pain, low patient tolerance, and elevated costs. Consequently, there has been a progressive transition in the administration route of antibody-based therapeutics from IV to SC injection. This shift is attributed not only to the reduced administration time but also to the feasibility of home-based administration (<xref rid="ref61" ref-type="bibr">61</xref>). In recent years, approximately 30% of the approved antibody-related drugs have been administered through SC injection (<xref rid="ref62" ref-type="bibr">62</xref>). Although several drugs have reached clinical trials, only denosumab and romosozumab have been approved by the EMA and FDA to treat postmenopausal osteoporosis (<xref rid="ref63" ref-type="bibr">63</xref>).</p><p>There were no statistically significant differences in safety and immune response between intramuscular and SC administration routes, according to a Phase 1 clinical trial (NCT00058435) (<xref rid="ref64" ref-type="bibr">64</xref>). Similarly, the findings of another Phase 1 clinical study (NCT00103545) were also promising (<xref rid="ref65" ref-type="bibr">65</xref>). However, a subsequent Phase 3 trial (NCT00418574) indicated that patients with ovarian cancer in first remission received no therapeutic benefits from abagovomab (<xref rid="ref66" ref-type="bibr">66</xref>).</p><p>Dalantercept, a recombinant fusion protein designed to target the activin receptor-like kinase 1 (ALK1) receptor, was evaluated in a Phase II clinical trial that comprised 28 patients with endometrial cancer. Patients were administered a dosage of 1.2&#x0202f;mg/kg subcutaneously every 3&#x0202f;weeks (NCT01642082). The majority of participants withdrew from the study primarily due to disease progression. It was concluded that dalantercept had inadequate efficacy as a single-agent treatment (<xref rid="ref67" ref-type="bibr">67</xref>). Additionally, a separate Phase II trial that evaluated dalantercept in patients with ovarian and fallopian tube cancers failed to exhibit any objective response (<xref rid="ref68" ref-type="bibr">68</xref>).</p><p>Hyaluronidase-zzxf/pertuzumab/trastuzumab is an SC injection that contains a fixed-dose combination of trastuzumab and pertuzumab, which has been approved for treating patients with HER2-positive breast cancer (<xref rid="ref69" ref-type="bibr">69</xref>). Currently, a Phase 2/3 clinical trial is underway to assess the efficacy of hyaluronidase-zzxf/pertuzumab/trastuzumab in patients with HER2-positive endometrial serous carcinoma (NCT05256225).</p><p>Furthermore, a Phase 2 clinical trial is currently underway to assess the efficacy of HMI-115 in patients with endometriosis-related pain. Herein, HMI-115 is administered SC on a bi-weekly basis.</p><p>This study shows that the availability of antibody-related drugs for SC administration is limited in the field of gynecology. This is because this route of administration is hindered by challenges such as immunogenicity, high viscosity, and protein aggregation (<xref rid="ref70" ref-type="bibr">70</xref>, <xref rid="ref71" ref-type="bibr">71</xref>). To enhance the SC delivery of antibodies, various strategies have been developed, including the combination of proprietary excipients and proteins to address the issues related to the ionic strength and hydrophobic regions of antibodies (<xref rid="ref60" ref-type="bibr">60</xref>).</p><p>Overall, the demand for SC antibodies is high on the market. However, significant obstacles persist and the SC administration is making ongoing advancements.</p></sec><sec id="sec18"><label>4.5.2</label><title>Potential targets</title><p>According to the results, the hottest and most potential targets for developing antibody-related drugs in gynecology are mesothelin, PD-1, FR&#x003b1;, HER2, and TIGIT. Mesothelin is a membrane-bound surface glycoprotein that is highly expressed in ovarian cancer, pancreatic adenocarcinoma, mesothelioma, and several other malignancies. However, its expression is limited in normal tissues (<xref rid="ref72" ref-type="bibr">72</xref>). Furthermore, mesothelin plays an important role in cell adhesion, drug resistance, and tumor metastasis, which makes it a potential therapeutic target for ovarian cancer (<xref rid="ref73" ref-type="bibr">73</xref>). Examples are amatuximab (NCT00325494), anetumab ravtansine (NCT03587311, NCT02751918), and RC88 (NCT06173037).</p><p>PD-1 is a checkpoint protein that belongs to the CD28 family. It is predominantly expressed in activated CD4&#x0202f;+&#x0202f;T cells, CD8&#x0202f;+&#x0202f;T cells, and peripheral B cells (<xref rid="ref74" ref-type="bibr">74</xref>). The PD-1 signaling pathway plays a significant role in the tumor microenvironment of various malignancies and contributes to T cell inactivation and depletion, which facilitates the evasion of antitumor immunity (<xref rid="ref75" ref-type="bibr">75</xref>). Consequently, PD-1 is a promising target for therapeutic strategies. Examples are balstilimab (NCT03495882, NCT03104699, NCT03894215, NCT06095674), BAT1308 (NCT06321068, NCT06123884), and rulonilimab (NCT06226350).</p><p>FR&#x003b1; is a glycoprotein attached to the membrane and is encoded by the FOLR1 gene (<xref rid="ref76" ref-type="bibr">76</xref>). It is critically involved in cell proliferation, DNA synthesis, and intracellular signaling, which are fundamental to tumorigenesis. The receptor is a promising target for the development of anticancer drugs due to its overexpression in various solid tumors, such as ovarian, lung, and breast cancers (<xref rid="ref77" ref-type="bibr">77</xref>). Examples are STRO-002 (NCT03748186, NCT05870748, and NCT05200364), IMGN151 (NCT05527184), and farletuzumab ecteribulin (NCT05613088).</p><p>HER2 is a constituent of the EGFR family of receptor tyrosine kinases (<xref rid="ref78" ref-type="bibr">78</xref>). Aberrations of the HER2 gene, including mutations, deletions, and amplifications, have been identified in ovarian, cervical, and endometrial cancers (<xref rid="ref79" ref-type="bibr">79</xref>). Examples are trastuzumab duocarmazine (NCT04205630), DP303c (NCT04828616), and BNT323/DB-1303 (NCT06340568).</p><p>TIGIT is a newly recognized immune checkpoint. It is predominantly expressed in natural killer cells, regulatory T cells, CD4&#x0202f;+&#x0202f;T cells, CD8&#x0202f;+&#x0202f;T cells, and tumor-infiltrating lymphocytes (<xref rid="ref80" ref-type="bibr">80</xref>). TIGIT is associated with the exhaustion of NK cells <italic>in vivo</italic> and is observed in individuals with various types of cancer (<xref rid="ref81" ref-type="bibr">81</xref>). Examples are tiragolumab (NCT04300647) and ociperlimab (NCT04693234).</p></sec></sec></sec><sec sec-type="conclusions" id="sec19"><label>5</label><title>Conclusion</title><p>This study provides a thorough review of clinical trials involving antibody-related drugs in the field of gynecology. The analysis revealed a growing prevalence of ADCs, bispecific antibodies, and Fc-fusion proteins. It has been found that these therapeutic modalities play a crucial role in advancing gynecological oncology. Meanwhile, it also explores the challenges associated with SC administration. The findings of this review may provide valuable insights and new ideas for future research on antibodies in gynecology.</p></sec></body><back><sec sec-type="data-availability" id="sec20"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="author-contributions" id="sec21"><title>Author contributions</title><p>XZ: Conceptualization, Data curation, Investigation, Methodology, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. LX: Conceptualization, Supervision, Writing &#x02013; review &#x00026; editing. FL: Data curation, Funding acquisition, Project administration, Supervision, Writing &#x02013; review &#x00026; editing. WC: Data curation, Methodology, Writing &#x02013; review &#x00026; editing. CZ: Supervision, Writing &#x02013; review &#x00026; editing. YD: Investigation, Supervision, Writing &#x02013; review &#x00026; editing. TW: Data curation, Writing &#x02013; review &#x00026; editing. SX: Supervision, Validation, Writing &#x02013; review &#x00026; editing. HD: Supervision, Validation, Writing &#x02013; review &#x00026; editing. MT: Supervision, Validation, Writing &#x02013; review &#x00026; editing. WG: Supervision, Validation, Writing &#x02013; review &#x00026; editing. EL: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Validation, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec23"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec24"><title>Generative AI statement</title><p>The author(s) declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec25"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>MA</given-names></name></person-group>. <article-title>Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer</article-title>. <source>Front Oncol</source>. (<year>2024</year>) <volume>14</volume>:<fpage>1379738</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2024.1379738</pub-id>, PMID: <pub-id pub-id-type="pmid">38746685</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alejandra</surname><given-names>WP</given-names></name>
<name><surname>Miriam Irene</surname><given-names>JP</given-names></name>
<name><surname>Fabio Antonio</surname><given-names>GS</given-names></name>
<name><surname>Patricia</surname><given-names>RR</given-names></name>
<name><surname>Elizabeth</surname><given-names>TA</given-names></name>
<name><surname>Aleman-Aguilar</surname><given-names>JP</given-names></name>
<etal/></person-group>. <article-title>Production of monoclonal antibodies for therapeutic purposes: a review</article-title>. <source>Int Immunopharmacol</source>. (<year>2023</year>) <volume>120</volume>:<fpage>110376</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110376</pub-id>, PMID: <pub-id pub-id-type="pmid">37244118</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinch</surname><given-names>MS</given-names></name>
<name><surname>Kraft</surname><given-names>Z</given-names></name>
<name><surname>Schwartz</surname><given-names>T</given-names></name></person-group>. <article-title>Monoclonal antibodies: trends in therapeutic success and commercial focus</article-title>. <source>Drug Discov Today</source>. (<year>2023</year>) <volume>28</volume>:<fpage>103415</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drudis.2022.103415</pub-id>, PMID: <pub-id pub-id-type="pmid">36280042</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>X-K</given-names></name>
<name><surname>Xu</surname><given-names>X-L</given-names></name>
<name><surname>Chen</surname><given-names>B-Y</given-names></name>
<name><surname>Su</surname><given-names>J</given-names></name>
<name><surname>Du</surname><given-names>Y-Z</given-names></name></person-group>. <article-title>Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments</article-title>. <source>J Nanobiotechnol</source>. (<year>2023</year>) <volume>21</volume>:<fpage>105</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12951-023-01857-8</pub-id>, PMID: <pub-id pub-id-type="pmid">36964609</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n-Sabroso</surname><given-names>C</given-names></name>
<name><surname>Lozza</surname><given-names>I</given-names></name>
<name><surname>Torres-Su&#x000e1;rez</surname><given-names>AI</given-names></name>
<name><surname>Fraguas-S&#x000e1;nchez</surname><given-names>AI</given-names></name></person-group>. <article-title>Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives</article-title>. <source>Pharmaceutics</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1705</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics13101705</pub-id>, PMID: <pub-id pub-id-type="pmid">34683998</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AC</given-names></name>
<name><surname>Roane</surname><given-names>BM</given-names></name>
<name><surname>Leath</surname><given-names>CA</given-names><suffix>3rd.</suffix></name></person-group>
<article-title>Novel therapeutics for recurrent cervical Cancer: moving towards personalized therapy</article-title>. <source>Drugs</source>. (<year>2020</year>) <volume>80</volume>:<fpage>217</fpage>&#x02013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40265-019-01249-z</pub-id>, PMID: <pub-id pub-id-type="pmid">31939072</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>DL</given-names></name>
<name><surname>Eskander</surname><given-names>RN</given-names></name>
<name><surname>O'Malley</surname><given-names>DM</given-names></name></person-group>. <article-title>Advances in ovarian Cancer care and unmet treatment needs for patients with platinum resistance: a narrative review</article-title>. <source>JAMA Oncol</source>. (<year>2023</year>) <volume>9</volume>:<fpage>851</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2023.0197</pub-id>, PMID: <pub-id pub-id-type="pmid">37079311</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perren</surname><given-names>TJ</given-names></name>
<name><surname>Swart</surname><given-names>AM</given-names></name>
<name><surname>Pfisterer</surname><given-names>J</given-names></name>
<name><surname>Ledermann</surname><given-names>JA</given-names></name>
<name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name>
<name><surname>Kristensen</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>A phase 3 trial of bevacizumab in ovarian cancer</article-title>. <source>N Engl J Med</source>. (<year>2011</year>) <volume>365</volume>:<fpage>2484</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1103799</pub-id><pub-id pub-id-type="pmid">22204725</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>N</given-names></name>
<name><surname>Dubot</surname><given-names>C</given-names></name>
<name><surname>Lorusso</surname><given-names>D</given-names></name>
<name><surname>Caceres</surname><given-names>MV</given-names></name>
<name><surname>Hasegawa</surname><given-names>K</given-names></name>
<name><surname>Shapira-Frommer</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer</article-title>. <source>N Engl J Med</source>. (<year>2021</year>) <volume>385</volume>:<fpage>1856</fpage>&#x02013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2112435</pub-id>, PMID: <pub-id pub-id-type="pmid">34534429</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Rustum</surname><given-names>NR</given-names></name>
<name><surname>Yashar</surname><given-names>CM</given-names></name>
<name><surname>Arend</surname><given-names>R</given-names></name>
<name><surname>Barber</surname><given-names>E</given-names></name>
<name><surname>Bradley</surname><given-names>K</given-names></name>
<name><surname>Brooks</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>NCCN guidelines&#x000ae; insights: cervical Cancer, version 1.2024</article-title>. <source>J Natl Compr Cancer Netw</source>. (<year>2023</year>) <volume>21</volume>:<fpage>1224</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.6004/jnccn.2023.0062</pub-id>, PMID: <pub-id pub-id-type="pmid">38081139</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Peng</surname><given-names>H</given-names></name>
<name><surname>Qi</surname><given-names>X</given-names></name>
<name><surname>Wu</surname><given-names>M</given-names></name>
<name><surname>Zhao</surname><given-names>X</given-names></name></person-group>. <article-title>Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2020</year>) <volume>5</volume>:<fpage>137</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-020-0199-6</pub-id>, PMID: <pub-id pub-id-type="pmid">32728057</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name>
<name><surname>He</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>Q</given-names></name></person-group>. <article-title>Immune checkpoint blockades in gynecological cancers: a review of clinical trials</article-title>. <source>Acta Obstet Gynecol Scand</source>. (<year>2022</year>) <volume>101</volume>:<fpage>941</fpage>&#x02013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1111/aogs.14412</pub-id>, PMID: <pub-id pub-id-type="pmid">35751489</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tymon-Rosario</surname><given-names>J</given-names></name>
<name><surname>Zeybek</surname><given-names>B</given-names></name>
<name><surname>Santin</surname><given-names>AD</given-names></name></person-group>. <article-title>Novel antibody-drug conjugates: current and future roles in gynecologic oncology</article-title>. <source>Curr Opin Obstet Gynecol</source>. (<year>2021</year>) <volume>33</volume>:<fpage>26</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1097/GCO.0000000000000642</pub-id>, PMID: <pub-id pub-id-type="pmid">32618744</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>B</given-names></name>
<name><surname>Rajeshuni</surname><given-names>N</given-names></name>
<name><surname>Tran</surname><given-names>EM</given-names></name>
<name><surname>Ludwig</surname><given-names>CA</given-names></name>
<name><surname>Tauqeer</surname><given-names>Z</given-names></name>
<name><surname>Weeks</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Characteristics of ophthalmology trials registered in ClinicalTrials.gov, 2007-2018</article-title>. <source>Am J Ophthalmol</source>. (<year>2020</year>) <volume>211</volume>:<fpage>132</fpage>&#x02013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajo.2019.11.004</pub-id>, PMID: <pub-id pub-id-type="pmid">31730839</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>JR</given-names></name>
<name><surname>Magnani</surname><given-names>CJ</given-names></name>
<name><surname>Turner</surname><given-names>BE</given-names></name>
<name><surname>Weeks</surname><given-names>BT</given-names></name>
<name><surname>Young</surname><given-names>AMP</given-names></name>
<name><surname>Lu</surname><given-names>CF</given-names></name>
<etal/></person-group>. <article-title>Early discontinuation, results reporting, and publication of gynecology clinical trials from 2007 to 2020</article-title>. <source>Obstet Gynecol</source>. (<year>2022</year>) <volume>139</volume>:<fpage>821</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1097/AOG.0000000000004735</pub-id>, PMID: <pub-id pub-id-type="pmid">35576341</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>JR</given-names></name>
<name><surname>Weeks</surname><given-names>BT</given-names></name>
<name><surname>Reyes</surname><given-names>GA</given-names></name>
<name><surname>Conway Fitzgerald</surname><given-names>A</given-names></name>
<name><surname>Zhang</surname><given-names>WY</given-names></name>
<name><surname>Lindsay</surname><given-names>SE</given-names></name>
<etal/></person-group>. <article-title>The obstetrical research landscape: a cross-sectional analysis of clinical trials from 2007-2020</article-title>. <source>Am J Obstet Gynecol MFM</source>. (<year>2021</year>) <volume>3</volume>:<fpage>100253</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajogmf.2020.100253</pub-id>, PMID: <pub-id pub-id-type="pmid">33043288</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JJH</given-names></name>
<name><surname>Hsu</surname><given-names>G</given-names></name>
<name><surname>Siden</surname><given-names>EG</given-names></name>
<name><surname>Thorlund</surname><given-names>K</given-names></name>
<name><surname>Mills</surname><given-names>EJ</given-names></name></person-group>. <article-title>An overview of precision oncology basket and umbrella trials for clinicians</article-title>. <source>CA Cancer J Clin</source>. (<year>2020</year>) <volume>70</volume>:<fpage>125</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21600</pub-id>, PMID: <pub-id pub-id-type="pmid">32031692</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haslam</surname><given-names>A</given-names></name>
<name><surname>Olivier</surname><given-names>T</given-names></name>
<name><surname>Tuia</surname><given-names>J</given-names></name>
<name><surname>Prasad</surname><given-names>V</given-names></name></person-group>. <article-title>A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target</article-title>. <source>Eur J Cancer</source>. (<year>2023</year>) <volume>178</volume>:<fpage>227</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2022.10.027</pub-id>, PMID: <pub-id pub-id-type="pmid">36493558</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billingham</surname><given-names>L</given-names></name>
<name><surname>Brown</surname><given-names>L</given-names></name>
<name><surname>Framke</surname><given-names>T</given-names></name>
<name><surname>Greystoke</surname><given-names>A</given-names></name>
<name><surname>Hovig</surname><given-names>E</given-names></name>
<name><surname>Mathur</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Histology independent drug development&#x02014;is this the future for cancer drugs?</article-title>
<source>Cancer Treat Rev</source>. (<year>2024</year>) <volume>123</volume>:<fpage>102674</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102674</pub-id>, PMID: <pub-id pub-id-type="pmid">38176220</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>FBT</given-names></name>
<name><surname>Sultova</surname><given-names>E</given-names></name>
<name><surname>Heinrich</surname><given-names>K</given-names></name>
<name><surname>Jung</surname><given-names>A</given-names></name>
<name><surname>Westphalen</surname><given-names>CB</given-names></name>
<name><surname>Tauber</surname><given-names>CV</given-names></name>
<etal/></person-group>. <article-title>Genetics and beyond: precision medicine real-world data for patients with cervical, vaginal or vulvar Cancer in a tertiary Cancer center</article-title>. <source>Int J Mol Sci</source>. (<year>2024</year>) <volume>25</volume>:<fpage>2345</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25042345</pub-id>, PMID: <pub-id pub-id-type="pmid">38397025</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>X</given-names></name>
<name><surname>Zhao</surname><given-names>Q</given-names></name>
<name><surname>Hui</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<name><surname>Lin</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>The global landscape of approved antibody therapies</article-title>. <source>Antibody Ther.</source> (<year>2022</year>) <volume>5</volume>:<fpage>233</fpage>&#x02013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1093/abt/tbac021</pub-id>, PMID: <pub-id pub-id-type="pmid">36213257</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Zheng</surname><given-names>L</given-names></name></person-group>. <article-title>Advances in the application of immune checkpoint inhibitors in gynecological tumors</article-title>. <source>Int Immunopharmacol</source>. (<year>2023</year>) <volume>117</volume>:<fpage>109774</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2023.109774</pub-id>, PMID: <pub-id pub-id-type="pmid">37012881</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name>
<name><surname>Hong</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Han</surname><given-names>Z</given-names></name>
<name><surname>Ma</surname><given-names>D</given-names></name></person-group>. <article-title>Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2023</year>) <volume>8</volume>:<fpage>320</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-023-01522-4</pub-id>, PMID: <pub-id pub-id-type="pmid">37635168</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullard</surname><given-names>A</given-names></name></person-group>. <article-title>FDA approves 100th monoclonal antibody product</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2021</year>) <volume>20</volume>:<fpage>491</fpage>&#x02013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1038/d41573-021-00079-7</pub-id>, PMID: <pub-id pub-id-type="pmid">33953368</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name>
<name><surname>Noh</surname><given-names>JJ</given-names></name>
<name><surname>Lee</surname><given-names>TK</given-names></name>
<name><surname>Kim</surname><given-names>SI</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Lee</surname><given-names>JW</given-names></name>
<etal/></person-group>. <article-title>Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: a multicenter study in Korea</article-title>. <source>Gynecol Oncol</source>. (<year>2022</year>) <volume>165</volume>:<fpage>369</fpage>&#x02013;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ygyno.2022.02.020</pub-id><pub-id pub-id-type="pmid">35277278</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>CH</given-names></name>
<name><surname>Lin</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>CT</given-names></name>
<name><surname>Ou</surname><given-names>YC</given-names></name>
<name><surname>Fu</surname><given-names>HC</given-names></name>
<name><surname>Wu</surname><given-names>CC</given-names></name>
<etal/></person-group>. <article-title>Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers</article-title>. <source>J Formos Med Assoc</source>. (<year>2024</year>) <volume>123</volume>:<fpage>487</fpage>&#x02013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jfma.2023.09.020</pub-id>, PMID: <pub-id pub-id-type="pmid">37852875</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>P</given-names></name>
<name><surname>Dwivedi</surname><given-names>SKD</given-names></name>
<name><surname>Bhattacharya</surname><given-names>R</given-names></name>
<name><surname>Mukherjee</surname><given-names>P</given-names></name>
<name><surname>Rao</surname><given-names>G</given-names></name></person-group>. <article-title>VEGF signaling: role in angiogenesis and beyond</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. (<year>2024</year>) <volume>1879</volume>:<fpage>189079</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbcan.2024.189079</pub-id>, PMID: <pub-id pub-id-type="pmid">38280470</pub-id>
</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yetkin-Arik</surname><given-names>B</given-names></name>
<name><surname>Kastelein</surname><given-names>AW</given-names></name>
<name><surname>Klaassen</surname><given-names>I</given-names></name>
<name><surname>Jansen</surname><given-names>C</given-names></name>
<name><surname>Latul</surname><given-names>YP</given-names></name>
<name><surname>Vittori</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. (<year>2021</year>) <volume>1875</volume>:<fpage>188446</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188446</pub-id>, PMID: <pub-id pub-id-type="pmid">33058997</pub-id>
</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name>
<name><surname>Zheng</surname><given-names>H</given-names></name>
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Shu</surname><given-names>T</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name></person-group>. <article-title>Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients</article-title>. <source>BMC Womens Health</source>. (<year>2023</year>) <volume>23</volume>:<fpage>178</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12905-023-02329-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37055754</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotaka</surname><given-names>S</given-names></name>
<name><surname>Kondo</surname><given-names>E</given-names></name>
<name><surname>Kawai</surname><given-names>Y</given-names></name>
<name><surname>Okamoto</surname><given-names>K</given-names></name>
<name><surname>Kishigami</surname><given-names>Y</given-names></name>
<name><surname>Yamawaki</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer</article-title>. <source>J Gynecol Oncol</source>. (<year>2023</year>) <volume>34</volume>:<fpage>e60</fpage>. doi: <pub-id pub-id-type="doi">10.3802/jgo.2023.34.e60</pub-id>, PMID: <pub-id pub-id-type="pmid">37170726</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewiecki</surname><given-names>EM</given-names></name></person-group>. <article-title>Monoclonal antibodies for the treatment of osteoporosis</article-title>. <source>Expert Opin Biol Ther</source>. (<year>2013</year>) <volume>13</volume>:<fpage>183</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.1517/14712598.2012.740006</pub-id>, PMID: <pub-id pub-id-type="pmid">23253281</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>ED</given-names></name></person-group>. <article-title>Denosumab: A Review in Postmenopausal Osteoporosis</article-title>. <source>Drugs Aging</source>. (<year>2018</year>) <volume>35</volume>:<fpage>163</fpage>&#x02013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40266-018-0525-7</pub-id>, PMID: <pub-id pub-id-type="pmid">29435849</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Wen</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name></person-group>. <article-title>Romosozumab in osteoporosis: yesterday, today and tomorrow</article-title>. <source>J Transl Med</source>. (<year>2023</year>) <volume>21</volume>:<fpage>668</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-023-04563-z</pub-id>, PMID: <pub-id pub-id-type="pmid">37759285</pub-id>
</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasso</surname><given-names>JM</given-names></name>
<name><surname>Tenchov</surname><given-names>R</given-names></name>
<name><surname>Bird</surname><given-names>R</given-names></name>
<name><surname>Iyer</surname><given-names>KA</given-names></name>
<name><surname>Ralhan</surname><given-names>K</given-names></name>
<name><surname>Rodriguez</surname><given-names>Y</given-names></name>
<etal/></person-group>. <article-title>The evolving landscape of antibody-drug conjugates: in depth analysis of recent research Progress</article-title>. <source>Bioconjug Chem</source>. (<year>2023</year>) <volume>34</volume>:<fpage>1951</fpage>&#x02013;<lpage>2000</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00374</pub-id>, PMID: <pub-id pub-id-type="pmid">37821099</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumontet</surname><given-names>C</given-names></name>
<name><surname>Reichert</surname><given-names>JM</given-names></name>
<name><surname>Senter</surname><given-names>PD</given-names></name>
<name><surname>Lambert</surname><given-names>JM</given-names></name>
<name><surname>Beck</surname><given-names>A</given-names></name></person-group>. <article-title>Antibody-drug conjugates come of age in oncology</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2023</year>) <volume>22</volume>:<fpage>641</fpage>&#x02013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-023-00709-2</pub-id>, PMID: <pub-id pub-id-type="pmid">37308581</pub-id>
</mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>DY</given-names></name>
<name><surname>Wu</surname><given-names>HX</given-names></name>
<name><surname>Meng</surname><given-names>Q</given-names></name>
<name><surname>Xu</surname><given-names>RH</given-names></name></person-group>. <article-title>Development of antibody-drug conjugates in cancer: overview and prospects</article-title>. <source>Cancer Commun (Lond)</source>. (<year>2024</year>) <volume>44</volume>:<fpage>3</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cac2.12517</pub-id>, PMID: <pub-id pub-id-type="pmid">38159059</pub-id>
</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpel</surname><given-names>HC</given-names></name>
<name><surname>Powell</surname><given-names>SS</given-names></name>
<name><surname>Pothuri</surname><given-names>B</given-names></name></person-group>. <article-title>Antibody-drug conjugates in gynecologic Cancer</article-title>. <source>Am Soc Clin Oncol Educ Book</source>. (<year>2023</year>) <volume>43</volume>:<fpage>e390772</fpage>. doi: <pub-id pub-id-type="doi">10.1200/EDBK_390772</pub-id>, PMID: <pub-id pub-id-type="pmid">37229642</pub-id>
</mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edoardo</surname><given-names>C</given-names></name>
<name><surname>Giuseppe</surname><given-names>C</given-names></name></person-group>. <article-title>Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate</article-title>. <source>Expert Opin Investig Drugs</source>. (<year>2024</year>) <volume>33</volume>:<fpage>851</fpage>&#x02013;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1080/13543784.2024.2376573</pub-id>, PMID: <pub-id pub-id-type="pmid">38967422</pub-id>
</mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name>
<name><surname>Makker</surname><given-names>V</given-names></name>
<name><surname>Oaknin</surname><given-names>A</given-names></name>
<name><surname>Oh</surname><given-names>DY</given-names></name>
<name><surname>Banerjee</surname><given-names>S</given-names></name>
<name><surname>Gonz&#x000e1;lez-Mart&#x000ed;n</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial</article-title>. <source>J Clin Oncol</source>. (<year>2024</year>) <volume>42</volume>:<fpage>47</fpage>&#x02013;<lpage>58</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.23.02005</pub-id>, PMID: <pub-id pub-id-type="pmid">37870536</pub-id>
</mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>T</given-names></name>
<name><surname>Hasegawa</surname><given-names>K</given-names></name>
<name><surname>Matsumoto</surname><given-names>K</given-names></name>
<name><surname>Mori</surname><given-names>M</given-names></name>
<name><surname>Hirashima</surname><given-names>Y</given-names></name>
<name><surname>Takehara</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Trastuzumab Deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine Carcinosarcoma (NCCH1615): the STATICE trial</article-title>. <source>J Clin Oncol</source>. (<year>2023</year>) <volume>41</volume>:<fpage>2789</fpage>&#x02013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.22.02558</pub-id>, PMID: <pub-id pub-id-type="pmid">36977309</pub-id>
</mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>EM</given-names></name>
<name><surname>Zeybek</surname><given-names>B</given-names></name>
<name><surname>Tymon-Rosario</surname><given-names>J</given-names></name>
<name><surname>Santin</surname><given-names>AD</given-names></name></person-group>. <article-title>Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer</article-title>. <source>Oncoscience</source>. (<year>2020</year>) <volume>7</volume>:<fpage>68</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncoscience.514</pub-id>, PMID: <pub-id pub-id-type="pmid">33195736</pub-id>
</mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardia</surname><given-names>A</given-names></name>
<name><surname>Messersmith</surname><given-names>WA</given-names></name>
<name><surname>Kio</surname><given-names>EA</given-names></name>
<name><surname>Berlin</surname><given-names>JD</given-names></name>
<name><surname>Vahdat</surname><given-names>L</given-names></name>
<name><surname>Masters</surname><given-names>GA</given-names></name>
<etal/></person-group>. <article-title>Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial</article-title>. <source>Ann Oncol</source>. (<year>2021</year>) <volume>32</volume>:<fpage>746</fpage>&#x02013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2021.03.005</pub-id>, PMID: <pub-id pub-id-type="pmid">33741442</pub-id>
</mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Yuan</surname><given-names>K</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
<name><surname>Hu</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Bispecific antibodies in cancer therapy: target selection and regulatory requirements</article-title>. <source>Acta Pharm Sin B</source>. (<year>2023</year>) <volume>13</volume>:<fpage>3583</fpage>&#x02013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.apsb.2023.05.023</pub-id>, PMID: <pub-id pub-id-type="pmid">37719370</pub-id>
</mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Xue</surname><given-names>Y</given-names></name>
<name><surname>Xie</surname><given-names>N</given-names></name>
<name><surname>Shen</surname><given-names>G</given-names></name></person-group>. <article-title>Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1291836</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2023.1291836</pub-id>, PMID: <pub-id pub-id-type="pmid">38106416</pub-id>
</mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name></person-group>. <article-title>Current landscape and future directions of bispecific antibodies in cancer immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>1035276</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.1035276</pub-id>, PMID: <pub-id pub-id-type="pmid">36389699</pub-id>
</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name>
<name><surname>Brinkmann</surname><given-names>U</given-names></name>
<name><surname>Reichert</surname><given-names>JM</given-names></name>
<name><surname>Kontermann</surname><given-names>RE</given-names></name></person-group>. <article-title>The present and future of bispecific antibodies for cancer therapy</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2024</year>) <volume>23</volume>:<fpage>301</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-024-00896-6</pub-id>, PMID: <pub-id pub-id-type="pmid">38448606</pub-id>
</mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>H</given-names></name>
<name><surname>Cai</surname><given-names>H</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical Cancer (COMPASSION-13): a phase 2 study</article-title>. <source>Clin Cancer Res</source>. (<year>2024</year>) <volume>30</volume>:<fpage>1501</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-3162</pub-id>, PMID: <pub-id pub-id-type="pmid">38372727</pub-id>
</mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Ji</surname><given-names>J</given-names></name>
<name><surname>Lou</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Feng</surname><given-names>M</given-names></name>
<name><surname>Xu</surname><given-names>N</given-names></name>
<etal/></person-group>. <article-title>Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)</article-title>. <source>Gynecol Oncol</source>. (<year>2022</year>) <volume>166</volume>:<fpage>S47</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0090-8258(22)01293-8</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keam</surname><given-names>SJ</given-names></name></person-group>. <article-title>Cadonilimab: First Approval</article-title>. <source>Drugs</source>. (<year>2022</year>) <volume>82</volume>:<fpage>1333</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40265-022-01761-9</pub-id>, PMID: <pub-id pub-id-type="pmid">35986837</pub-id>
</mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>S</given-names></name>
<name><surname>Corr</surname><given-names>BR</given-names></name>
<name><surname>Culm-Merdek</surname><given-names>K</given-names></name>
<name><surname>Mockbee</surname><given-names>C</given-names></name>
<name><surname>Youssoufian</surname><given-names>H</given-names></name></person-group>. <article-title>Navicixizumab plus paclitaxel shows clinical benefit in platinum-resistant ovarian Cancer</article-title>. <source>Cancer Discov</source>. (<year>2022</year>) <volume>12</volume>:<fpage>OF6</fpage>. doi: <pub-id pub-id-type="doi">10.1158/2159-8290.CD-RW2022-073</pub-id>, PMID: <pub-id pub-id-type="pmid">35485873</pub-id>
</mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimeno</surname><given-names>A</given-names></name>
<name><surname>Moore</surname><given-names>KN</given-names></name>
<name><surname>Gordon</surname><given-names>M</given-names></name>
<name><surname>Chugh</surname><given-names>R</given-names></name>
<name><surname>Diamond</surname><given-names>JR</given-names></name>
<name><surname>Aljumaily</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors</article-title>. <source>Investig New Drugs</source>. (<year>2019</year>) <volume>37</volume>:<fpage>461</fpage>&#x02013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10637-018-0665-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30229512</pub-id>
</mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>S</given-names></name>
<name><surname>Corr</surname><given-names>BR</given-names></name>
<name><surname>Culm-Merdek</surname><given-names>K</given-names></name>
<name><surname>Mockbee</surname><given-names>C</given-names></name>
<name><surname>Youssoufian</surname><given-names>H</given-names></name>
<name><surname>Stagg</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Phase Ib study of Navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube Cancer</article-title>. <source>J Clin Oncol</source>. (<year>2022</year>) <volume>40</volume>:<fpage>2568</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.21.01801</pub-id>, PMID: <pub-id pub-id-type="pmid">35439029</pub-id>
</mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duivelshof</surname><given-names>BL</given-names></name>
<name><surname>Murisier</surname><given-names>A</given-names></name>
<name><surname>Camperi</surname><given-names>J</given-names></name>
<name><surname>Fekete</surname><given-names>S</given-names></name>
<name><surname>Beck</surname><given-names>A</given-names></name>
<name><surname>Guillarme</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Therapeutic fc-fusion proteins: current analytical strategies</article-title>. <source>J Sep Sci</source>. (<year>2021</year>) <volume>44</volume>:<fpage>35</fpage>&#x02013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jssc.202000765</pub-id>, PMID: <pub-id pub-id-type="pmid">32914936</pub-id>
</mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname><given-names>R</given-names></name>
<name><surname>Zolbanin</surname><given-names>NM</given-names></name>
<name><surname>Rafatpanah</surname><given-names>H</given-names></name>
<name><surname>Majidi</surname><given-names>J</given-names></name>
<name><surname>Kazemi</surname><given-names>T</given-names></name></person-group>. <article-title>Fc-fusion proteins in therapy: An updated view</article-title>. <source>Curr Med Chem</source>. (<year>2017</year>) <volume>24</volume>:<fpage>1228</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.2174/0929867324666170113112759</pub-id>, PMID: <pub-id pub-id-type="pmid">28088904</pub-id>
</mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gameiro</surname><given-names>SR</given-names></name>
<name><surname>Strauss</surname><given-names>J</given-names></name>
<name><surname>Gulley</surname><given-names>JL</given-names></name>
<name><surname>Schlom</surname><given-names>J</given-names></name></person-group>. <article-title>Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGF&#x003b2;RII agent: current status</article-title>. <source>Exp Biol Med (Maywood)</source>. (<year>2022</year>) <volume>247</volume>:<fpage>1124</fpage>&#x02013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1177/15353702221089910</pub-id>, PMID: <pub-id pub-id-type="pmid">35473390</pub-id>
</mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oaknin</surname><given-names>A</given-names></name>
<name><surname>Ghamande</surname><given-names>SA</given-names></name>
<name><surname>Kasamatsu</surname><given-names>Y</given-names></name>
<name><surname>Gil-Martin</surname><given-names>M</given-names></name>
<name><surname>Grau-Bejar</surname><given-names>JF</given-names></name>
<name><surname>Garcia-Duran</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Phase I trial of first-line Bintrafusp alfa in patients with locally advanced or persistent/recurrent/metastatic cervical Cancer</article-title>. <source>Clin Cancer Res</source>. (<year>2024</year>) <volume>30</volume>:<fpage>975</fpage>&#x02013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1829</pub-id>, PMID: <pub-id pub-id-type="pmid">38165683</pub-id>
</mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birrer</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Yunokawa</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>BG</given-names></name>
<name><surname>Oppermann</surname><given-names>CP</given-names></name>
<etal/></person-group>. <article-title>Bintrafusp alfa for recurrent or metastatic cervical Cancer after platinum failure: a nonrandomized controlled trial</article-title>. <source>JAMA Oncol</source>. (<year>2024</year>) <volume>10</volume>:<fpage>1204</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2024.2145</pub-id>, PMID: <pub-id pub-id-type="pmid">39052242</pub-id>
</mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KM</given-names></name>
<name><surname>Friedman</surname><given-names>CF</given-names></name></person-group>. <article-title>Bifunctional blockade: a novel immunotherapy approach for cervical Cancer</article-title>. <source>Clin Cancer Res</source>. (<year>2022</year>) <volume>28</volume>:<fpage>5238</fpage>&#x02013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-1779</pub-id>, PMID: <pub-id pub-id-type="pmid">35947045</pub-id>
</mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J</given-names></name>
<name><surname>Tang</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Zhou</surname><given-names>Q</given-names></name>
<name><surname>Peng</surname><given-names>J</given-names></name>
<name><surname>Lou</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF&#x003b2;, for recurrent or metastatic cervical Cancer: a clinical expansion cohort of a phase I study</article-title>. <source>Clin Cancer Res</source>. (<year>2022</year>) <volume>28</volume>:<fpage>5297</fpage>&#x02013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-0346</pub-id>, PMID: <pub-id pub-id-type="pmid">35653122</pub-id>
</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitiot</surname><given-names>A</given-names></name>
<name><surname>Heuz&#x000e9;-Vourc'h</surname><given-names>N</given-names></name>
<name><surname>S&#x000e9;cher</surname><given-names>T</given-names></name></person-group>. <article-title>Alternative routes of Administration for Therapeutic Antibodies-State of the art</article-title>. <source>Antibodies (Basel)</source>. (<year>2022</year>) <volume>11</volume>:<fpage>56</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antib11030056</pub-id>, PMID: <pub-id pub-id-type="pmid">36134952</pub-id>
</mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname><given-names>M</given-names></name>
<name><surname>Sequeira</surname><given-names>J</given-names></name>
<name><surname>Sei&#x000e7;a</surname><given-names>R</given-names></name>
<name><surname>Veiga</surname><given-names>F</given-names></name>
<name><surname>Serra</surname><given-names>J</given-names></name>
<name><surname>Santos</surname><given-names>AC</given-names></name>
<etal/></person-group>. <article-title>Subcutaneous delivery of monoclonal antibodies: how do we get there?</article-title>
<source>J Control Release</source>. (<year>2018</year>) <volume>286</volume>:<fpage>301</fpage>&#x02013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.08.001</pub-id>, PMID: <pub-id pub-id-type="pmid">30077735</pub-id>
</mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strickley</surname><given-names>RG</given-names></name>
<name><surname>Lambert</surname><given-names>WJ</given-names></name></person-group>. <article-title>A review of formulations of commercially available antibodies</article-title>. <source>J Pharm Sci</source>. (<year>2021</year>) <volume>110</volume>:<fpage>2590</fpage>&#x02013;<lpage>608.e56</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xphs.2021.03.017</pub-id>, PMID: <pub-id pub-id-type="pmid">33789155</pub-id>
</mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayakawa</surname><given-names>T</given-names></name>
<name><surname>Miyazaki</surname><given-names>A</given-names></name>
<name><surname>Saito</surname><given-names>M</given-names></name>
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Takahashi</surname><given-names>J</given-names></name>
<name><surname>Nakamura</surname><given-names>Y</given-names></name></person-group>. <article-title>Denosumab versus romosozumab for postmenopausal osteoporosis treatment</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>11801</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-91248-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34083636</pub-id>
</mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultes</surname><given-names>BC</given-names></name>
<name><surname>Smith</surname><given-names>LM</given-names></name>
<name><surname>Nicodemus</surname><given-names>CF</given-names></name></person-group>. <article-title>Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer</article-title>. <source>Clin Cancer Res</source>. (<year>2007</year>) <volume>13</volume>:<fpage>4026</fpage>&#x02013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2664</pub-id>, PMID: <pub-id pub-id-type="pmid">17606738</pub-id>
</mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfisterer</surname><given-names>J</given-names></name>
<name><surname>du Bois</surname><given-names>A</given-names></name>
<name><surname>Sehouli</surname><given-names>J</given-names></name>
<name><surname>Loibl</surname><given-names>S</given-names></name>
<name><surname>Reinartz</surname><given-names>S</given-names></name>
<name><surname>Reuss</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR</article-title>. <source>Ann Oncol</source>. (<year>2006</year>) <volume>17</volume>:<fpage>1568</fpage>&#x02013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdl357</pub-id>, PMID: <pub-id pub-id-type="pmid">17005631</pub-id>
</mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbatini</surname><given-names>P</given-names></name>
<name><surname>Harter</surname><given-names>P</given-names></name>
<name><surname>Scambia</surname><given-names>G</given-names></name>
<name><surname>Sehouli</surname><given-names>J</given-names></name>
<name><surname>Meier</surname><given-names>W</given-names></name>
<name><surname>Wimberger</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Abagovomab as maintenance therapy in patients with epithelial ovarian Cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO&#x02014;the MIMOSA study</article-title>. <source>J Clin Oncol</source>. (<year>2013</year>) <volume>31</volume>:<fpage>1554</fpage>&#x02013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2012.46.4057</pub-id>, PMID: <pub-id pub-id-type="pmid">23478059</pub-id>
</mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makker</surname><given-names>V</given-names></name>
<name><surname>Filiaci</surname><given-names>VL</given-names></name>
<name><surname>Chen</surname><given-names>LM</given-names></name>
<name><surname>Darus</surname><given-names>CJ</given-names></name>
<name><surname>Kendrick</surname><given-names>JE</given-names></name>
<name><surname>Sutton</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study 0229N</article-title>. <source>Gynecol Oncol</source>. (<year>2015</year>) <volume>138</volume>:<fpage>24</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ygyno.2015.04.006</pub-id>, PMID: <pub-id pub-id-type="pmid">25888978</pub-id>
</mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>RA</given-names></name>
<name><surname>Deng</surname><given-names>W</given-names></name>
<name><surname>Makker</surname><given-names>V</given-names></name>
<name><surname>Collins</surname><given-names>Y</given-names></name>
<name><surname>Gray</surname><given-names>H</given-names></name>
<name><surname>Debernardo</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study</article-title>. <source>Gynecol Oncol</source>. (<year>2018</year>) <volume>150</volume>:<fpage>466</fpage>&#x02013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ygyno.2018.06.017</pub-id>, PMID: <pub-id pub-id-type="pmid">30041929</pub-id>
</mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AR</given-names></name>
<name><surname>Im</surname><given-names>SA</given-names></name>
<name><surname>Mattar</surname><given-names>A</given-names></name>
<name><surname>Colomer</surname><given-names>R</given-names></name>
<name><surname>Stroyakovskii</surname><given-names>D</given-names></name>
<name><surname>Nowecki</surname><given-names>Z</given-names></name>
<etal/></person-group>. <article-title>Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study</article-title>. <source>Lancet Oncol</source>. (<year>2021</year>) <volume>22</volume>:<fpage>85</fpage>&#x02013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(20)30536-2</pub-id>, PMID: <pub-id pub-id-type="pmid">33357420</pub-id>
</mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awwad</surname><given-names>S</given-names></name>
<name><surname>Angkawinitwong</surname><given-names>U</given-names></name></person-group>. <article-title>Overview of antibody drug delivery</article-title>. <source>Pharmaceutics</source>. (<year>2018</year>) <volume>10</volume>:<fpage>83</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pharmaceutics10030083</pub-id>, PMID: <pub-id pub-id-type="pmid">29973504</pub-id>
</mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bittner</surname><given-names>B</given-names></name>
<name><surname>Schmidt</surname><given-names>J</given-names></name></person-group>. <article-title>Advancing subcutaneous dosing regimens for biotherapeutics: clinical strategies for expedited market access</article-title>. <source>BioDrugs</source>. (<year>2024</year>) <volume>38</volume>:<fpage>23</fpage>&#x02013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40259-023-00626-1</pub-id>, PMID: <pub-id pub-id-type="pmid">37831325</pub-id>
</mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>R</given-names></name>
<name><surname>Bera</surname><given-names>T</given-names></name>
<name><surname>Pastan</surname><given-names>I</given-names></name></person-group>. <article-title>Mesothelin: a new target for immunotherapy</article-title>. <source>Clin Cancer Res</source>. (<year>2004</year>) <volume>10</volume>:<fpage>3937</fpage>&#x02013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0801</pub-id><pub-id pub-id-type="pmid">15217923</pub-id>
</mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Zhou</surname><given-names>J</given-names></name></person-group>. <article-title>Insights into the role of Mesothelin as a diagnostic and therapeutic target in ovarian carcinoma</article-title>. <source>Front Oncol</source>. (<year>2020</year>) <volume>10</volume>:<fpage>1263</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2020.01263</pub-id>, PMID: <pub-id pub-id-type="pmid">32983962</pub-id>
</mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Long</surname><given-names>S</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>Y</given-names></name>
<etal/></person-group>. <article-title>The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<fpage>964442</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.964442</pub-id>, PMID: <pub-id pub-id-type="pmid">36177034</pub-id>
</mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name>
<name><surname>Kang</surname><given-names>K</given-names></name>
<name><surname>Chen</surname><given-names>P</given-names></name>
<name><surname>Zeng</surname><given-names>Z</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Xiong</surname><given-names>W</given-names></name>
<etal/></person-group>. <article-title>Regulatory mechanisms of PD-1/PD-L1 in cancers</article-title>. <source>Mol Cancer</source>. (<year>2024</year>) <volume>23</volume>:<fpage>108</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-024-02023-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38762484</pub-id>
</mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>T</given-names></name>
<name><surname>Muminovic</surname><given-names>M</given-names></name>
<name><surname>Nano</surname><given-names>O</given-names></name>
<name><surname>Vulfovich</surname><given-names>M</given-names></name></person-group>. <article-title>Folate receptor alpha-a novel approach to Cancer therapy</article-title>. <source>Int J Mol Sci</source>. (<year>2024</year>) <volume>25</volume>:<fpage>1046</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25021046</pub-id>, PMID: <pub-id pub-id-type="pmid">38256120</pub-id>
</mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scaranti</surname><given-names>M</given-names></name>
<name><surname>Cojocaru</surname><given-names>E</given-names></name>
<name><surname>Banerjee</surname><given-names>S</given-names></name>
<name><surname>Banerji</surname><given-names>U</given-names></name></person-group>. <article-title>Exploiting the folate receptor &#x003b1; in oncology</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2020</year>) <volume>17</volume>:<fpage>349</fpage>&#x02013;<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41571-020-0339-5</pub-id>, PMID: <pub-id pub-id-type="pmid">32152484</pub-id>
</mixed-citation></ref><ref id="ref78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>K</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name>
<name><surname>Tai</surname><given-names>H</given-names></name>
<name><surname>Zhong</surname><given-names>X</given-names></name>
<name><surname>Luo</surname><given-names>T</given-names></name>
<name><surname>Zheng</surname><given-names>H</given-names></name></person-group>. <article-title>HER2-targeted therapies in cancer: a systematic review</article-title>. <source>Biomark Res</source>. (<year>2024</year>) <volume>12</volume>:<fpage>16</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40364-024-00565-1</pub-id>, PMID: <pub-id pub-id-type="pmid">38308374</pub-id>
</mixed-citation></ref><ref id="ref79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DY</given-names></name>
<name><surname>Bang</surname><given-names>YJ</given-names></name></person-group>. <article-title>HER2-targeted therapies&#x02014;a role beyond breast cancer</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2020</year>) <volume>17</volume>:<fpage>33</fpage>&#x02013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41571-019-0268-3</pub-id>, PMID: <pub-id pub-id-type="pmid">31548601</pub-id>
</mixed-citation></ref><ref id="ref80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauvin</surname><given-names>JM</given-names></name>
<name><surname>Zarour</surname><given-names>HM</given-names></name></person-group>. <article-title>TIGIT in cancer immunotherapy</article-title>. <source>J Immunother Cancer</source>. (<year>2020</year>) <volume>8</volume>:<fpage>e000957</fpage>. doi: <pub-id pub-id-type="doi">10.1136/jitc-2020-000957</pub-id>, PMID: <pub-id pub-id-type="pmid">32900861</pub-id>
</mixed-citation></ref><ref id="ref81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Gu</surname><given-names>Z</given-names></name>
<name><surname>Jiang</surname><given-names>Z</given-names></name>
<name><surname>Zhao</surname><given-names>S</given-names></name>
<name><surname>Song</surname><given-names>Y</given-names></name>
<etal/></person-group>. <article-title>Targeting TIGIT for cancer immunotherapy: recent advances and future directions</article-title>. <source>Biomark Res</source>. (<year>2024</year>) <volume>12</volume>:<fpage>7</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40364-023-00543-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38229100</pub-id>
</mixed-citation></ref></ref-list></back></article>